Is brigatinib/brigatinib (Embry) safe to take long-term?

Brigatinib/Brigatinib (Brigatinib), as an ALK inhibitor, has been proven to have significant efficacy in the treatment of patients with ALK mutation-positive non-small cell lung cancer (NSCLC). It mainly achieves anti-tumor effects by inhibiting the proliferation of cancer cells caused by ALK gene mutations. Because brigatinib can delay disease progression and improve patients' quality of life, many patients hope to take the drug long-term during treatment.

In clinical studies, brigatinib was found to have good long-term efficacy and acceptable safety. For most patients, brigatinib continues to maintain its efficacy after several months or more of treatment, and side effects are generally manageable. However, long-term use of brigatinib still requires monitoring under the guidance of a physician, as some side effects may increase with prolonged use.

Common long-term side effects include respiratory problems, such as pneumonia and interstitial lung disease, and cardiovascular side effects, such as high blood pressure and irregular heartbeats. Although these side effects may not necessarily affect all patients, doctors will conduct individualized treatment based on the patient's specific situation and regularly evaluate the safety and effectiveness of the drug. In order to minimize these side effects, patients need to undergo regular pulmonary function, cardiovascular system and other related examinations while taking brigatinib so that problems can be detected in time and corresponding measures can be taken.

The therapeutic effect of brigatinib on central nervous system (CNS) metastases has also been widely recognized, which is particularly important for patients with brain metastases. However, patients may still develop new brain metastases or other side effects during long-term use, so long-term use of this drug needs to be strictly monitored by professional doctors.

Reference materials:https://www.alunbrig.com/